微譜聚焦生物醫(yī)藥領(lǐng)域，致力于成為您值得信賴的醫(yī)藥研發(fā)伙伴。我們密切關(guān)注全球生物醫(yī)藥行業(yè)發(fā)展趨勢(shì)，整合出藥品包材理、化學(xué)藥品質(zhì)量研究、生物制品研究、醫(yī)療器械檢測(cè)服務(wù)等多平臺(tái)服務(wù)，以完備的質(zhì)量體系、高速的交付周期、豐富的項(xiàng)目經(jīng)驗(yàn)及持續(xù)擴(kuò)張的能力布局，2024年5月，微譜藥物及醫(yī)療器械實(shí)驗(yàn)室成功通過(guò)美國(guó)FDA現(xiàn)場(chǎng)核查。我們的報(bào)告得到了中國(guó)、歐盟、美國(guó)、WHO等國(guó)際主要市場(chǎng)監(jiān)管機(jī)構(gòu)的認(rèn)可，成功助力3500余家藥物及醫(yī)療器械企業(yè)加速產(chǎn)品上市進(jìn)程！ 

Weipu focuses on the field of biomedicine and is committed to becoming your trusted pharmaceutical research and development partner. We closely monitor the development trends of the global biopharmaceutical industry, integrating multiple platform services such as drug packaging material management, chemical drug quality research, biological product research, and medical device testing services. With a complete quality system, high-speed delivery cycle, rich project experience, and continuous expansion capability layout, in May 2024, Weipu Drug and Medical Device Laboratory successfully passed the on-site inspection of the US FDA. Our report has been recognized by major international market regulatory agencies such as China, the European Union, the United States, and WHO, successfully assisting over 3500 pharmaceutical and medical device companies in accelerating their product launch processes!